Recently, it has been demonstrated that mesenchymal stem cells (MSCs) engineered to release IL-7 and IL-12 increase the anti-tumor activity of CAR-T cells with specificity for the carcinoembryonic antigen (CEA), acting against colorectal carcinoma cells and altering the inflammatory action of Th2 in the tumor milieu [132]. The gene discussed is CEACAM5; the disease is neoplasm.